Hepatitis C virus–cardiovascular disease relationship in dialysis patients

The Hepatitis C virus–cardiovascular disease relationship in dialysis patients describes the connection between HCV infection and an increased burden of cardiovascular disease and cardiovascular death among people receiving long-term dialysis. HCV-positive dialysis patients show higher mortality in several large observational studies, and the association persists after adjustment for many demographic and clinical factors. At the same time, the evidence is not uniform: some meta-analytic estimates do not demonstrate a statistically significant excess in cardiovascular mortality, so HCV should be understood as an important contributor to risk rather than a sole or universally decisive cause.

Definition and Clinical Setting

HCV is a systemic infection rather than a disorder confined to the liver. It can produce autoimmune, dermatological, and renal disease, and it occurs in a population already exposed to substantial cardiovascular risk from chronic kidney disease, hypertension, metabolic abnormalities, inflammation, and dialysis itself. The wider clinical burden is considerable: global prevalence has been estimated at about 3%, or roughly 170 million infected people, while chronic HCV in dialysis patients is associated with reduced survival and more frequent liver-related complications.

The dialysis setting also has a distinctive epidemiological history. During the early 1990s, patients receiving hemodialysis were recognized as a high-risk group because of earlier transfusion exposure and suspected nosocomial transmission within dialysis units. As blood-donor screening became more sensitive and erythropoiesis-stimulating agents reduced the need for transfusion, the risk from blood products fell dramatically. The estimated post-transfusion risk declined from about 0.5% per blood unit in the 1980s to approximately 0.0001%, or one case per million units, in the United States. This change shifted attention toward infection control and the continuing systemic consequences of HCV in the dialysis population.

Evidence for Cardiovascular Risk

Several cohort studies connect anti-HCV positivity with cardiovascular outcomes. In a population-based survey of 2,778 patients receiving long-term dialysis in the DaVita system, anti-HCV positivity was associated with a hazard ratio of 1.28 for all-cause mortality and 1.48 for cardiovascular death after adjustment for case-mix variables. Adjustment for available surrogates of the malnutrition-inflammation syndrome partly weakened the cardiovascular association, but it did not eliminate it. In patients younger than 65 years, the association remained particularly strong, with a hazard ratio of 1.80 for cardiovascular mortality after adjustment for case-mix and malnutrition-inflammation covariates.

A subsequent survey of 13,664 patients followed for three years found a hazard ratio of 1.25 for all-cause mortality among those with HCV antibodies. The relative risk of cardiovascular mortality remained elevated across nearly all patient groups, although it did not reach statistical significance in every subgroup. Another population-based study likewise found a significantly increased risk of cardiovascular death among anti-HCV-positive patients after accounting for age, pre-existing cardiovascular disease, and other patient characteristics, with a hazard ratio of 1.34. That analysis censored patients at transplantation to reduce confounding from post-transplant outcomes, while a follow-up approach extending through transplantation produced a similar adjusted hazard ratio of 1.27.

The overall mortality signal is also visible in meta-analytic evidence. Across seven observational studies involving 11,589 dialysis patients, anti-HCV antibody positivity was associated with an adjusted relative risk of 1.34 for all-cause mortality, with a 95% confidence interval of 1.13 to 1.59. Hepatocellular carcinoma and cirrhosis were more frequent causes of death among anti-HCV-positive patients, and the unadjusted risk of liver-related mortality was markedly higher. By contrast, the same meta-analysis produced an unadjusted relative risk of 0.95 for cardiovascular-related mortality, with a 95% confidence interval of 0.76 to 1.18 and no statistical significance. This contrast explains why the relationship is clinically concerning but cannot be reduced to a single uncontested estimate.

Possible Biological and Clinical Pathways

One proposed pathway runs through chronic inflammation and nutritional deterioration. HCV-infected dialysis patients have a higher prevalence of hypoalbuminemia than their non-HCV-infected counterparts. In a United States survey of 69,294 patients receiving long-term dialysis, mean albumin was 3.68 ± 0.45 g/dl in anti-HCV-positive patients compared with 3.76 ± 0.41 g/dl in those without HCV antibodies. Chronic infection may worsen nutritional status and inflammation, and those changes may contribute to cardiovascular mortality in a population already vulnerable to both.

HCV may also intensify metabolic mechanisms associated with vascular disease. The infection has been linked with liver steatosis, insulin resistance, and hypoadiponectinemia, alongside conventional dialysis-related cardiovascular risks such as hypertension, hypercholesterolemia, and hyperhomocysteinemia. Traditional risk factors explain only part of the excess mortality observed in dialysis patients, leaving room for HCV-related inflammation, metabolic disturbance, and impaired nutritional reserve to act as additional influences.

A prospective vascular study supplied a more direct physiological signal. Among 94 dialysis patients, 17 of whom were HCV-positive, HCV viremia and mean blood pressure were independently associated with high aortic stiffness, defined by a mean carotid-femoral pulse-wave velocity of at least 10.0 m/s. The odds ratio for the association with HCV viremia was 9.7, although the confidence interval was wide, extending from 1.18 to 81.19. Kaplan-Meier curves also showed a significant difference in cerebrovascular and cardiovascular event-free survival between patients who were HCV RNA-positive and those who were HCV RNA-negative. These findings support a possible atherogenic role for active viremia through aggravation of metabolic syndrome and dyslipidemia, while the limited sample size counsels caution.

Diagnosis, Disease Classification, and Confounding

The cardiovascular relationship depends on distinguishing exposure markers from active infection. Anti-HCV antibodies identify prior immune recognition but do not by themselves establish ongoing viral replication. Active chronic infection requires both anti-HCV positivity and detectable HCV RNA, with molecular assays capable of detecting concentrations around 15 IU/ml. In dialysis and transplant candidates, screening therefore requires confirmation of viremia rather than treating antibody positivity as equivalent to active disease.

The broader evaluation of active HCV infection must include hepatic and extrahepatic disease. Liver injury can be assessed by biopsy or noninvasive methods such as FibroScan, and the latter may permit repeated yearly monitoring of fibrosis while avoiding approximately half of liver biopsies. HCV can also cause mixed cryoglobulinemia, a systemic vasculitis characterized by arthralgia, purpura, neuropathy, hypocomplementemia, and kidney disease. Renal manifestations include proteinuria, hematuria, reduced estimated glomerular filtration rate, nephritic syndrome, and nephrotic syndrome. These complications matter to cardiovascular interpretation because systemic inflammation, renal injury, and worsening nutritional status can converge on the same clinical outcomes.

Interpretation is further complicated by the background risk of the dialysis population. Dialysis patients commonly have anemia, hypertension, vascular access problems, malnutrition, inflammation, and multiple comorbidities, while symptoms such as fatigue and cognitive impairment are frequent regardless of HCV serologic status. Consequently, an observed association between HCV and cardiovascular death may reflect several interacting pathways rather than a single viral mechanism. The partial attenuation of risk after adjustment for malnutrition-inflammation measures illustrates this problem without resolving it.

Clinical and Research Significance

The relationship makes HCV more than a liver-focused concern in dialysis care. HCV assessment should combine antibody testing with HCV RNA confirmation, evaluation of fibrosis and extrahepatic disease, and attention to nutritional, inflammatory, metabolic, and vascular status. The evidence also strengthens the rationale for preventing transmission in dialysis units, since infection carries consequences that extend beyond hepatic injury and may affect survival even when liver disease is clinically quiet.

Treatment decisions must be interpreted in the context of evolving antiviral therapy. In the period discussed by the source, pegylated interferon and ribavirin produced sustained virologic response in more than half of patients overall, while first-generation direct-acting antiviral triple therapy with telaprevir or boceprevir increased sustained virologic response among genotype 1 patients by roughly 20 to 30 percentage points. These treatments were limited by rash, anemia, cost, adherence, viral resistance, and drug interactions. Whether antiviral treatment reduces cardiovascular mortality in dialysis patients remains uncertain, but improvement in infection control, systemic inflammation, nutritional status, and quality of life could provide benefits beyond virologic clearance.

The relationship therefore occupies an important but carefully bounded place in dialysis medicine. HCV is associated with excess all-cause mortality, repeated observational signals of cardiovascular death, vascular stiffness, and metabolic and inflammatory conditions that plausibly promote atherosclerosis. Yet the conflicting meta-analytic cardiovascular estimate and the burden of confounding prevent a simplistic causal claim. The strongest interpretation is cumulative: active HCV may add a vascular and inflammatory burden to an already fragile cardiovascular system, making accurate diagnosis, prevention, comprehensive risk assessment, and appropriately selected antiviral therapy central to the care of dialysis patients.